Moreover, a novel variant in neutrophil cytosolic factor 2 (NCF2) has been found in 4% of patients with VEO-IBD compared with 0.2% of controls, and this variant results in reduced protein binding and partial inhibition of oxidase function [16]. The gene discussed is NCF2; the disease is inflammatory bowel disease.